Toxic epidermal necrolysis/Stevens-Johnson syndrome: Current trends in management

ANZ Journal of Surgery

Volumn 77, Issue 8, 2007, Pages 671-676

  Dalli, Rachel L ^a,b   Kumar, Rohit ^a   Kennedy, Peter ^a   Maitz, Peter ^a   Lee, Stephen ^a   Johnson, Rae ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b NONE   (Australia)

Author keywords

Acticoat ; Lyell syndrome; Nanocrystalline silver; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFOTAXIME; COTRIMOXAZOLE; ERYTHROMYCIN; INDOMETACIN; ITRACONAZOLE; NANOCRYSTAL; PENICILLIN G; PETROLATUM; PHENYTOIN; RIFABUTIN; VENLAFAXINE;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GAUZE DRESSING; HEALING; HUMAN; MALE; MEDICAL RECORD REVIEW; MUCOSA; RETROSPECTIVE STUDY; SEPSIS; SKIN DEFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREND STUDY; WOUND DRESSING;

ADOLESCENT; ADULT; AGED; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; POLYESTERS; POLYETHYLENES; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME;

EID: 34447305228     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2007.04184.x     Document Type: Article

References (36)

1. Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am. J. Dis. Child. 1922 24 : 526 33.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol. 1956 68 : 355 61.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 1993 129 : 92 6.
4. Rappersberger K, Foedinger D. Treatment of erythema multiforme, Stevens-Johnsons syndrome, and toxic epidermal necrolysis. Dermatol. Ther. 2002 15 : 397 408.
5. Roujeau J. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol. 1994 102 : 28S 30S.
6. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 1995 333 : 1600 607.
7. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schopf E. Low N-acetylating capacity in patients with Stevens-Johnson and toxic epidermal necrolysis. Exp. Dermatol. 1995 4 : 313 16.
8. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin. Cutan. Med. Surg. 1996 15 : 258 66.
9. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions. Stevens-Johnson and toxic epidermal necrolysis. ACI Int. 2002 109 : 115 61.
10. Posadas SJ, Padial A, Torres MJ et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J. Allergy Clin. Immunol. 2002 109 : 115 61.
11. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrilha J. Increased interleukin 10, tumour necrosis factor a, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J. Am. Acad. Dermatol. 2002 47 : 58 62.
12. Herndon DN. Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burns intensive care units without the prolonged use of corticosteroids. J. Am. Coll. Surg. 1995 180 : 340 42.
13. Green D, Law E, Still JM. An approach to the management of toxic epidermal necrolysis in a burn centre. Burns 1993 19 : 411 14.
14. Palmieri TL, Greenhalgh DG, Saffle JR et al. A multicenter review of toxic epidermal necrolysis treated in US burns centers at the end of the twentieth century. J. Burn Care Rehabil. 2002 23 : 87 96.
15. Yarbrough DR. Experience with toxic epidermal necrolysis treated in a Burns centre. J. Burn Care Rehabil. 1996 17 : 30 33.
16. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to a regional burn center. Plast. Reconstr. Surg. 1998 102 : 1018 22.
17. Keleman JJ 3rd., Cioffi WG, McManus WF, Mason AD, Pruitt BA. Burn center care for patients with toxic epidermal necrolysis. J. Am. Coll. Surg. 1995 180 : 273 8.
18. Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J. Burn Care Rehabil. 1997 18 : 417 20.
19. Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J. Burn Care Rehabil. 2000 21 : 199 204.
20. Bastuji-Garin S, Fouchard N, Bertochi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 2000 115 : 149 53.
21. Imahara SD, Holmes JH 4th., Heimbach DM et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J. Burn Care Res. 2006 27 : 270 75.
22. Wong K, Kennedy P, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson and toxic epidermal necrolysis. Australas. J. Dermatol. 1999 40 : 131 4.
23. Patterson R, Grammer LC, Greenberger PA et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc. 1992 12 : 89 95.
24. Patterson R, Miller M, Kaplan M et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann. Allergy 1994 73 : 27 34.
25. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann. Surg. 1986 204 : 503 12.
26. Avakian R, Flowers F, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J. Am. Acad. Dermatol. 1991 25 : 69 79.
27. Spies M, Sandford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001 108 : 1162 8.
28. Patterson R, Dykewicz MS, Gonzalzles A et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest 1990 98 : 331 6.
29. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch. Dermatol. 2003 139 : 39 43.
30. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch. Dermatol. 2003 139 : 33 6.
31. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J. Burn Care Rehabil. 2004 25 : 246 55.
32. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol. 2005 153 : 241 53.
33. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Management of toxic epidermal necrolysis with cyclosporin A. J. Trauma 2000 48 : 473 8.
34. Tredget EE, Shankowsky HA, Groenveld A, Burrell R. A matched pair randomised study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burns wounds. J. Burn Care Rehabil. 1998 19 : 531 7.
35. Dunn K, Edward-Jones V. The role of Acticoat™ with nanocrystalline silver in the management of burns. Burns 2004 30 : S1 S9.
36. Heimbach D, Engrav L, Marvin J, Harnan T, Grube B. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987 257 : 2171 5.